Comment diagnostiquer une hyperuricémie ?

Un test sanguin mesure le taux d'acide urique pour diagnostiquer l'hyperuricémie.

Quels tests pour la goutte ?

L'analyse du liquide synovial et des tests sanguins pour l'acide urique sont utilisés.

Quels symptômes indiquent une crise de goutte ?

Douleur intense, rougeur et gonflement d'une articulation, souvent le gros orteil.

Comment évaluer une maladie liée aux purines ?

Des tests génétiques et des analyses biochimiques peuvent être nécessaires.

Quel rôle des purines dans le diagnostic ?

Les niveaux de purines peuvent indiquer des troubles métaboliques ou des maladies rénales.

Quels sont les symptômes de l'hyperuricémie ?

Souvent asymptomatique, mais peut causer des douleurs articulaires et des calculs rénaux.

Quels signes de goutte aiguë ?

Douleur intense, rougeur, chaleur et gonflement d'une articulation, souvent nocturne.

Comment se manifeste une crise de goutte ?

Une douleur soudaine et sévère dans une articulation, souvent accompagnée d'inflammation.

Quels symptômes des troubles des purines ?

Fatigue, douleurs articulaires, et parfois des problèmes rénaux ou hépatiques.

Quels symptômes d'une maladie de Wilson ?

Accumulation de cuivre, troubles neurologiques, et symptômes hépatiques.

Comment prévenir l'hyperuricémie ?

Adopter un régime pauvre en purines et éviter l'alcool et les boissons sucrées.

Quelles habitudes pour éviter la goutte ?

Maintenir un poids santé, rester hydraté et limiter les aliments riches en purines.

Comment réduire le risque de calculs rénaux ?

Boire beaucoup d'eau et éviter les aliments riches en oxalates et purines.

Quels conseils diététiques pour les purines ?

Limiter les viandes rouges, les fruits de mer et les boissons alcoolisées.

Comment surveiller les niveaux d'acide urique ?

Des tests sanguins réguliers pour surveiller les niveaux d'acide urique et ajuster le régime.

Comment traiter l'hyperuricémie ?

Des médicaments comme les inhibiteurs de la xanthine oxydase et des changements alimentaires.

Quel traitement pour la goutte ?

Anti-inflammatoires non stéroïdiens (AINS) et colchicine pour soulager la douleur.

Comment prévenir les crises de goutte ?

Éviter les aliments riches en purines et maintenir une hydratation adéquate.

Quels médicaments pour les troubles des purines ?

Des médicaments spécifiques selon le trouble, comme les uricosuriques pour l'hyperuricémie.

Comment gérer les calculs rénaux liés aux purines ?

Hydratation, modifications alimentaires et parfois intervention chirurgicale.

Quelles complications de la goutte ?

Arthrite chronique, dépôts de tophus et risque accru de maladies cardiovasculaires.

Quels risques liés à l'hyperuricémie ?

Peut entraîner des calculs rénaux, des maladies rénales et des problèmes cardiovasculaires.

Comment l'hyperuricémie affecte-t-elle les reins ?

Peut provoquer une néphropathie urique, entraînant des lésions rénales.

Quelles complications des troubles des purines ?

Peuvent inclure des problèmes hépatiques, neurologiques et des troubles métaboliques.

Quels effets à long terme de la goutte ?

Peut entraîner des dommages articulaires permanents et des complications systémiques.

Quels facteurs de risque pour l'hyperuricémie ?

Obésité, consommation excessive d'alcool, régime riche en purines et antécédents familiaux.

Qui est à risque de goutte ?

Les hommes, les personnes obèses et celles ayant des antécédents familiaux de goutte.

Quels médicaments augmentent le risque d'hyperuricémie ?

Diurétiques, aspirine à faible dose et certains médicaments immunosuppresseurs.

Quel rôle de l'alimentation dans les purines ?

Une alimentation riche en viandes rouges, fruits de mer et boissons sucrées augmente le risque.

Comment l'âge influence-t-il l'hyperuricémie ?

Le risque d'hyperuricémie augmente avec l'âge, surtout chez les hommes après 40 ans.

Purines - Informations médicales vérifiées

The Impact of Receipt of Information on Prostate-Specific Antigen Testing on Screening with the Prostate-Specific Antigen Test.

08 2023

DOI: 10.1007/s13187-023-02264-1 PMID: 36652189

There is controversy on prostate cancer screening with the prostate-specific antigen (PSA) test in the USA, and as a result, there has been an increased push for physicians to have a thorough discussi...

Male Humans United States Prostatic Neoplasms Prostate-Specific Antigen +4 autres

Prostate-Specific Antigen Screening in Transgender Patients.

Jan 2023

DOI: 10.1016/j.eururo.2022.09.007 PMID: 36344317

Approximately 0.4-1.3% of the worldwide population is transgender. Although the exact prevalence is unknown, there is an increase in open identification as transgender. Among transgender women (TW), t... To assess our current understanding of CaP incidence and prostate-specific antigen (PSA) screening in TW.... We performed a nonsystematic narrative review of all PubMed publications through June 2022 according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement. Given ... There is no consensus regarding PSA screening in TW from any of the major societies, and TW are largely absent from guidelines. Case report data suggest that TW with CaP may have more aggressive disea... We are in the infancy of our understanding of PSA screening in TW. Important avenues for future research include understanding the risks/benefits of PSA screening in TW, how best to mitigate potential... We examined patterns of prostate cancer screening for transgender women. Little is known about prostate cancer incidence or screening in this population. Additional research is needed to establish gui...

Male Humans Prostate-Specific Antigen Prostatic Neoplasms Early Detection of Cancer +2 autres

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.

10 2022

DOI: 10.1002/pros.24414 PMID: 35860909

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is increasingly incorporated in the therapeutic algorithm of patients with metastatic castration-resistant prostate cancer ... In this bicentric analysis, we included 184 mCRPC patients treated with... A total of 114/184 patients (62.0%) showed any PSA decline (PSA response >50%, 55/184 [29.9%]). For individuals exhibiting a PSA decline >50%, OS of 19 months was significantly longer relative to nonr... In mCRPC patients scheduled for RLT, early biochemical response was tightly linked to prolonged survival, irrespective of the magnitude of PSA decline. As such, even in patients with PSA decrease of l...

Antigens, Surface Dipeptides Glutamate Carboxypeptidase II Heterocyclic Compounds, 1-Ring Humans +8 autres

Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals.

04 2023

DOI: 10.1016/j.clgc.2022.09.007 PMID: 36253300

In this study, it was aimed to investigate the reliability of total prostate-specific antigen (t-PSA) in prostate cancer screening in hyperglycemic (≥126 mg/dL) individuals.... This research was planned as a cross-sectional retrospective study. Three hundred eleven cases which underwent biopsy with the suspicion of prostate cancer in the hospital were included in the study. ... It was determined that the t-PSA measurement was higher in the patient group with cancer (P < .001). It was determined that the median t-PSA levels of the intermediate and high cancer groups were high... As a contribution to literature, we found that the t-PSA test lost its sensitivity in cases with plasma glucose levels above normal. Loss of sensitivity may result in underdiagnosis in prostate cancer...

Male Humans Prostate-Specific Antigen Prostatic Neoplasms Retrospective Studies +3 autres

[Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer].

Nov 2023

DOI: 10.1007/s00120-023-02189-z PMID: 37702749

Prostate-specific membrane antigen (PSMA) hybrid imaging is a promising new technique gaining importance in the field of prostate cancer (PCa) diagnosis and treatment planning. By combining PSMA radio...

Male Humans Prostate Positron Emission Tomography Computed Tomography Prostatic Neoplasms +2 autres

Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.

03 Jun 2024

DOI: 10.1001/jamanetworkopen.2024.14582 PMID: 38833252

Prostate-specific antigen (PSA) screening for prostate cancer is controversial but may be associated with benefit for certain high-risk groups.... To evaluate associations of county-level PSA screening prevalence with prostate cancer outcomes, as well as variation by sociodemographic and clinical factors.... This cohort study used data from cancer registries based in 8 US states on Hispanic, non-Hispanic Black, and non-Hispanic White men aged 40 to 99 years who received a diagnosis of prostate cancer betw... County-level PSA screening prevalence was estimated using the Behavior Risk Factor Surveillance System survey data from 2004, 2006, 2008, 2010, and 2012 and weighted by population characteristics.... Multivariable logistic, Cox proportional hazards regression, and competing risks models were fit to estimate adjusted odds ratios (AOR) and adjusted hazard ratios (AHR) for associations of county-leve... Of 814 987 men with prostate cancer, the mean (SD) age was 67.3 (9.8) years, 7.8% were Hispanic, 12.2% were non-Hispanic Black, and 80.0% were non-Hispanic White; 17.0% had advanced disease. There wer... This population-based cohort study of men with prostate cancer suggests that higher county-level prevalence of PSA screening was associated with lower odds of advanced disease, all-cause mortality, an...

Humans Male Prostatic Neoplasms Prostate-Specific Antigen Aged +8 autres

Prostate cancer risk prediction based on clinical factors and prostate-specific antigen.

03 Jun 2023

DOI: 10.1186/s12894-023-01259-w PMID: 37270476

The incidence rate of prostate cancer (PCa) has continued to rise in Korea. This study aimed to construct and evaluate a 5-year PCa risk prediction model using a cohort with PSA < 10 ng/mL by incorpor... The PCa risk prediction model including PSA levels and individual risk factors was constructed using a cohort of 69,319 participants from the Kangbuk Samsung Health Study. 201 registered PCa incidence... The risk prediction model included age, smoking status, alcohol consumption, family history of PCa, past medical history of dyslipidemia, cholesterol levels, and PSA level. Especially, an elevated PSA... Our risk prediction model was effective in predicting PCa in a population according to PSA levels. When PSA levels are inconclusive, an assessment of both PSA and specific individual risk factors (e.g...

Male Humans Prostate-Specific Antigen Prostatic Neoplasms Risk Factors +4 autres

Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer.

Dec 2023

DOI: 10.1080/0284186X.2023.2254480 PMID: 37713321

For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, ... Prostate biopsies from 92 patients with metastatic hormone naïve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performe... The immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognos... PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The re...

Male Humans Prostatic Neoplasms Prostate-Specific Antigen Prognosis +4 autres

Value of serum free prostate-specific antigen density in the diagnosis of prostate cancer.

Dec 2023

DOI: 10.1007/s11845-023-03448-w PMID: 37414978

To investigate the value of serum free prostate-specific antigen density (fPSAD) in the diagnosis of prostate cancer (PCa).... The data of 558 patients who underwent transrectal ultrasound-guided prostate biopsy were retrospectively analyzed. According to the pathological results, the patients were divided into a PCa group an... tPSA, PSAD, (f/t)/PSAD, and fPSAD had high accuracy in predicting PCa with AUC values of 0.820, 0.900, 0.846, and 0.867. fPSAD showed lower diagnostic sensitivity but significantly higher specificity ... With the optimal cutoff value of 0.062, fPSAD has a higher diagnostic value for PCa than tPSA, f/tPSA, (f/t)/PSAD, and PSAD, and can well predict the risk of PCa, significantly improve the clinical di...

Male Humans Middle Aged Prostate-Specific Antigen Retrospective Studies +5 autres

Serum prostate specific antigen is a good indicator of prostatic volume in men with benign prostatic hyperplasia.

15 Dec 2022

DOI: 10.4102/phcfm.v14i1.3736 PMID: 36546488

Benign prostatic hyperplasia (BPH) is the most common cause of bladder outlet obstruction in men over the age of 50 years. An association between the prostate specific antigen (PSA), International Pro... To determine the correlation between the PSA, IPSS and PV in men of African descent.... This was a cross sectional analysis involving 92 patients diagnosed as having symptomatic BPH at the Ho Teaching Hospital.... The data were collected using standardised questionnaires. The IPSS determined urinary symptom severity. The PV was determined using a transabdominal ultrasound machine. Serum PSA was retrieved from t... The mean PV was 61.04 cm3 ± 21.95 cm3, the mean PSA was 4.21 ng/mL ± 3.85 ng/mL, and mean IPSS of 21.59 ± 3.78. The Pearson's correlation between PV and PSA was 0.283 (p = 0.01), between PV and IPSS w... This study showed that serum PSA has a positive correlation with PV. However, IPSS had no significant association with PSA or PV in patients with BPH.Contribution: This study provides insights into th...

Male Humans Middle Aged Prostatic Hyperplasia Prostate-Specific Antigen +2 autres

Purines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Adénine

Allopurinol

Mercaptopurine

Purinones

Roscovitine

Citrate de sildénafil

Tioguanine

Amino-2 purine

Cytokinine

Famciclovir

Ténofovir

Hypoxanthines

Xanthines

Kinétine

Zéatine

Guanine

Hypoxanthine

Caféine

Théobromine

Théophylline

Acide urique

Xanthine

Aciclovir

8-Azaguanine

Pentoxifylline

Diphylline

Xanthine(isobutyl-3 methyl-1)

Nicotinate de xanthinol

Ganciclovir

Valaciclovir

Valganciclovir

Auteurs principaux

Sources (10000 au total)